Dicot Pharma presents interim report Q3 2025 and invites to a live broadcast

Third quarter, July-September 2025

• Net sales amounted to SEK 0.0 (0.0) million
• Earnings after financial items amounted to SEK -16.1 (-10.2) million
• Earnings per share amounted to SEK -0.01 (-0.01)

"As a company, we have now moved to the next level, with results qualifying us to proceed in our clinical development.", comments Elin Trampe, CEO.

Significant events during the quarter

• When all participants had made their final clinic visit in August, the clinical part of the phase 2a study was completed.
• As of August 27, Dicot Pharma is included in the MSCI Global Micro Cap Index, which is the investment basis for index funds and institutional asset managers.
• In September, the US investment bank Oppenheimer highlights in a report the strong link between erectile dysfunction and longevity and highlights the potency drug candidate LIB-01 as particularly interesting.

Significant events after the quarter

• Topline results from the clinical phase 2a study were announced October 23 and show an improvement of erectile function at week 4, following a single 3-day oral treatment of LIB-01. Moreover, the effect was sustained at week 8. LIB-01 was well tolerated.

The interim report and the study result from phase 2a will be presented by CEO Elin Trampe, CSO Charlotta Gauffin, and CFO Björn Petersson in a live broadcast from Direkt Studio tomorrow Friday October 24 at 12.00 CEST. A link to the broadcast will be available at WEBINAR or via a link at www.dicotpharma.com. Questions can be posed prior to the meeting to [email protected]. The broadcast may be viewed afterwards via the same link.

For further information re. the report, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: [email protected]

Björn Petersson, CFO
Phone: +46 76 109 00 00
E-mail: [email protected]

About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market. 

Dicot Pharma is listed on Nasdaq First North and has approximately 16,300 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.

This information is information that Dicot Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-10-23 16:00 CEST.